Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Growth in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 77,000 shares, an increase of 40.8% from the October 31st total of 54,700 shares. Based on an average trading volume of 337,300 shares, the days-to-cover ratio is currently 0.2 days. Approximately 5.8% of the company’s stock are sold short.

Institutional Trading of Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC purchased a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned 1.08% of Sonoma Pharmaceuticals at the end of the most recent quarter. 1.95% of the stock is currently owned by hedge funds and other institutional investors.

Sonoma Pharmaceuticals Stock Performance

Shares of NASDAQ:SNOA remained flat at $2.79 during trading on Friday. The company’s stock had a trading volume of 36,732 shares, compared to its average volume of 201,845. Sonoma Pharmaceuticals has a 52-week low of $2.52 and a 52-week high of $9.37. The stock has a market capitalization of $3.74 million, a PE ratio of -0.56 and a beta of 1.38. The firm has a fifty day simple moving average of $2.90 and a two-hundred day simple moving average of $1.54.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.